Clinical Research Directory

Inclusion Criteria: * Adult (≥ 18 years); * Non-specific low back pain (≤ 5 days); * Pain score (VAS) ≥ 5 (during mobilization); * Inability to walk easily (failure of the "Get Up and Go" test in less than 20 seconds). Exclusion Criteria: * Low back pain of known specific origin: spine surgery, spine trauma, discal hernia, facet joint, radicular (sciatica, cruralgia, meralgia paresthetica), muscle pain, cancer-related or rheumatological disease; * Referred or chronic pain; * Patients with opioids (acute or chronic pain and/or misuse); * Contraindication to regional anaesthesia; * Contraindication to ropivacaine, dexamethasone, sodium chloride, NSAID, paracetamol, tramadol; * Known hypersensitivity to ropivacaine, dexamethasone, other amide-type local anesthetics, or any of the excipients; * Addiction to drugs, alcohol or medication; * Patients with anticoagulants for a curative use (not preventive); * Patients with cancer or risk of bone metastasis or; severe osteoporosis; * Acute inflammatory diseases (e.g., rheumatoid arthritis, ankylosing spondylitis…); * Patient with severe hypotension or uncontrolled hypertension or; Heart Block (uncorrected second- or third-degree heart block without a pacemaker) or; severe bradycardia; * Patients with severe liver or renal disease or peptic ulcer disease; * Presence of infection or sepsis at the injection site; * Patients with uncontrolled bacterial, viral, or protozoan infections or; systemic fungal infections or; active untreated tuberculosis or; active ocular herpes simplex infections; * Patients with uncontrolled diabetes mellitus; * Patients with glaucoma or history of severe glaucoma; * Patients with severe psychiatric conditions; * Subject unable to read or/and write (inability to complete a self-administered questionnaire); * Unavailability for follow up during 6 months; * Participation in another clinical trial involving an investigational medicinal product or medical device within 4 weeks preceding the screening date; * Pregnancy in progress or planned during the study period or breastfeeding women (Art. L1121-5 of the French Public Health Code); * Women of childbearing potential (WOCBP) without a negative of highly sensitive pregnancy test before inclusion or not using a highly effective method of contraception; * Patients protected by law (Art. L1121-6 and L1121-8 of the French Public Health Code): Individuals deprived of their liberty by judicial or administrative decision, minors, adults under law protection or unable to express their consent or patient under guardianship or curatorship; * Patients not covered by a French social security scheme or not benefiting from such a scheme; * Absence of signed informed consent form before inclusion from the patient; * Patient already included in the study.